Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma

R. Pazdur, B. Bready, J. A. Ajani, J. L. Abbruzzese, Avi Markowitz, S. Sugarman, D. Jones, B. Levin

    Research output: Contribution to journalArticle

    Abstract

    Phase II trials of the novel biologic combination isotretinoin (13-cis- retinoic acid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinomas of the skin and cervix. Because this combination has had limited study in other tumors, we initiated a phase II trial of this regimen in patients with metastatic colorectal adenocarcinoma. Sixteen patients with measurable metastatic colon carcinoma who had received no previous chemotherapy were entered on the trial. Patients received recombinant interferon alfa-2a, 6 million units a day subcutaneously, and isotretinoin, 1 mg/kg per day orally in two divided doses. Patients were evaluated for response after 8 weeks of treatment and then continued on therapy until progressive disease was documented. We did not observe complete or partial responses. Two patients experienced minor responses in measurable pulmonary metastases lasting 12 and 8 weeks. Grade 3-4 toxic reactions included fatigue (5 patients), granulocytopenia (6 patients), neurotoxicity (2 patients), and elevated serum triglyceride levels (2 patients). Although this combination has demonstrated significant activity in squamous cell carcinomas of the skin and cervix, our results suggest that it has little therapeutic activity against advanced colorectal adenocarcinomas.

    Original languageEnglish (US)
    Pages (from-to)436-438
    Number of pages3
    JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
    Volume18
    Issue number5
    StatePublished - 1995

    Fingerprint

    Isotretinoin
    Colorectal Neoplasms
    Cervix Uteri
    Squamous Cell Carcinoma
    Adenocarcinoma
    interferon alfa-2a
    Skin
    Agranulocytosis
    Poisons
    Fatigue
    Colon
    Triglycerides
    Therapeutics
    Neoplasm Metastasis
    Carcinoma
    Drug Therapy
    Lung

    Keywords

    • 13-cis-Retinoic acid
    • Colon carcinoma
    • Colorectal carcinoma
    • Interferons
    • Isotretinoin
    • Recombinant interferon alfa- 2a
    • Rectal carcinoma
    • Retinoids

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Pazdur, R., Bready, B., Ajani, J. A., Abbruzzese, J. L., Markowitz, A., Sugarman, S., ... Levin, B. (1995). Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 18(5), 436-438.

    Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. / Pazdur, R.; Bready, B.; Ajani, J. A.; Abbruzzese, J. L.; Markowitz, Avi; Sugarman, S.; Jones, D.; Levin, B.

    In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 18, No. 5, 1995, p. 436-438.

    Research output: Contribution to journalArticle

    Pazdur, R, Bready, B, Ajani, JA, Abbruzzese, JL, Markowitz, A, Sugarman, S, Jones, D & Levin, B 1995, 'Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 18, no. 5, pp. 436-438.
    Pazdur, R. ; Bready, B. ; Ajani, J. A. ; Abbruzzese, J. L. ; Markowitz, Avi ; Sugarman, S. ; Jones, D. ; Levin, B. / Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1995 ; Vol. 18, No. 5. pp. 436-438.
    @article{9b6868adcdc34dbea4122fb3068ca69d,
    title = "Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma",
    abstract = "Phase II trials of the novel biologic combination isotretinoin (13-cis- retinoic acid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinomas of the skin and cervix. Because this combination has had limited study in other tumors, we initiated a phase II trial of this regimen in patients with metastatic colorectal adenocarcinoma. Sixteen patients with measurable metastatic colon carcinoma who had received no previous chemotherapy were entered on the trial. Patients received recombinant interferon alfa-2a, 6 million units a day subcutaneously, and isotretinoin, 1 mg/kg per day orally in two divided doses. Patients were evaluated for response after 8 weeks of treatment and then continued on therapy until progressive disease was documented. We did not observe complete or partial responses. Two patients experienced minor responses in measurable pulmonary metastases lasting 12 and 8 weeks. Grade 3-4 toxic reactions included fatigue (5 patients), granulocytopenia (6 patients), neurotoxicity (2 patients), and elevated serum triglyceride levels (2 patients). Although this combination has demonstrated significant activity in squamous cell carcinomas of the skin and cervix, our results suggest that it has little therapeutic activity against advanced colorectal adenocarcinomas.",
    keywords = "13-cis-Retinoic acid, Colon carcinoma, Colorectal carcinoma, Interferons, Isotretinoin, Recombinant interferon alfa- 2a, Rectal carcinoma, Retinoids",
    author = "R. Pazdur and B. Bready and Ajani, {J. A.} and Abbruzzese, {J. L.} and Avi Markowitz and S. Sugarman and D. Jones and B. Levin",
    year = "1995",
    language = "English (US)",
    volume = "18",
    pages = "436--438",
    journal = "American Journal of Clinical Oncology",
    issn = "0277-3732",
    publisher = "Lippincott Williams and Wilkins",
    number = "5",

    }

    TY - JOUR

    T1 - Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma

    AU - Pazdur, R.

    AU - Bready, B.

    AU - Ajani, J. A.

    AU - Abbruzzese, J. L.

    AU - Markowitz, Avi

    AU - Sugarman, S.

    AU - Jones, D.

    AU - Levin, B.

    PY - 1995

    Y1 - 1995

    N2 - Phase II trials of the novel biologic combination isotretinoin (13-cis- retinoic acid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinomas of the skin and cervix. Because this combination has had limited study in other tumors, we initiated a phase II trial of this regimen in patients with metastatic colorectal adenocarcinoma. Sixteen patients with measurable metastatic colon carcinoma who had received no previous chemotherapy were entered on the trial. Patients received recombinant interferon alfa-2a, 6 million units a day subcutaneously, and isotretinoin, 1 mg/kg per day orally in two divided doses. Patients were evaluated for response after 8 weeks of treatment and then continued on therapy until progressive disease was documented. We did not observe complete or partial responses. Two patients experienced minor responses in measurable pulmonary metastases lasting 12 and 8 weeks. Grade 3-4 toxic reactions included fatigue (5 patients), granulocytopenia (6 patients), neurotoxicity (2 patients), and elevated serum triglyceride levels (2 patients). Although this combination has demonstrated significant activity in squamous cell carcinomas of the skin and cervix, our results suggest that it has little therapeutic activity against advanced colorectal adenocarcinomas.

    AB - Phase II trials of the novel biologic combination isotretinoin (13-cis- retinoic acid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinomas of the skin and cervix. Because this combination has had limited study in other tumors, we initiated a phase II trial of this regimen in patients with metastatic colorectal adenocarcinoma. Sixteen patients with measurable metastatic colon carcinoma who had received no previous chemotherapy were entered on the trial. Patients received recombinant interferon alfa-2a, 6 million units a day subcutaneously, and isotretinoin, 1 mg/kg per day orally in two divided doses. Patients were evaluated for response after 8 weeks of treatment and then continued on therapy until progressive disease was documented. We did not observe complete or partial responses. Two patients experienced minor responses in measurable pulmonary metastases lasting 12 and 8 weeks. Grade 3-4 toxic reactions included fatigue (5 patients), granulocytopenia (6 patients), neurotoxicity (2 patients), and elevated serum triglyceride levels (2 patients). Although this combination has demonstrated significant activity in squamous cell carcinomas of the skin and cervix, our results suggest that it has little therapeutic activity against advanced colorectal adenocarcinomas.

    KW - 13-cis-Retinoic acid

    KW - Colon carcinoma

    KW - Colorectal carcinoma

    KW - Interferons

    KW - Isotretinoin

    KW - Recombinant interferon alfa- 2a

    KW - Rectal carcinoma

    KW - Retinoids

    UR - http://www.scopus.com/inward/record.url?scp=0029090033&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0029090033&partnerID=8YFLogxK

    M3 - Article

    C2 - 7572763

    AN - SCOPUS:0029090033

    VL - 18

    SP - 436

    EP - 438

    JO - American Journal of Clinical Oncology

    JF - American Journal of Clinical Oncology

    SN - 0277-3732

    IS - 5

    ER -